Search

George W. Kosturko

Examiner (ID: 15764, Phone: (571)270-5903 , Office: P/1628 )

Most Active Art Unit
1628
Art Unit(s)
1628, 1621
Total Applications
821
Issued Applications
383
Pending Applications
110
Abandoned Applications
359

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 20192171 [patent_doc_number] => 20250268881 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-08-28 [patent_title] => STABLE PHARMACEUTICAL COMPOSITIONS OF APIXABAN [patent_app_type] => utility [patent_app_number] => 19/207781 [patent_app_country] => US [patent_app_date] => 2025-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12104 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19207781 [rel_patent_id] =>[rel_patent_doc_number] =>)
19/207781
STABLE PHARMACEUTICAL COMPOSITIONS OF APIXABAN May 13, 2025 Pending
Array ( [id] => 20192171 [patent_doc_number] => 20250268881 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-08-28 [patent_title] => STABLE PHARMACEUTICAL COMPOSITIONS OF APIXABAN [patent_app_type] => utility [patent_app_number] => 19/207781 [patent_app_country] => US [patent_app_date] => 2025-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12104 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19207781 [rel_patent_id] =>[rel_patent_doc_number] =>)
19/207781
STABLE PHARMACEUTICAL COMPOSITIONS OF APIXABAN May 13, 2025 Pending
Array ( [id] => 19798889 [patent_doc_number] => 20250064814 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-27 [patent_title] => FORMULATION PRODUCTION PROCESS [patent_app_type] => utility [patent_app_number] => 18/946234 [patent_app_country] => US [patent_app_date] => 2024-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4076 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18946234 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/946234
Formulation production process Nov 12, 2024 Issued
Array ( [id] => 19798889 [patent_doc_number] => 20250064814 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-27 [patent_title] => FORMULATION PRODUCTION PROCESS [patent_app_type] => utility [patent_app_number] => 18/946234 [patent_app_country] => US [patent_app_date] => 2024-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4076 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18946234 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/946234
Formulation production process Nov 12, 2024 Issued
Array ( [id] => 19798900 [patent_doc_number] => 20250064825 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-27 [patent_title] => NASAL COMPOSITIONS COMPRISING ALCAFTADINE [patent_app_type] => utility [patent_app_number] => 18/943124 [patent_app_country] => US [patent_app_date] => 2024-11-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8007 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18943124 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/943124
NASAL COMPOSITIONS COMPRISING ALCAFTADINE Nov 10, 2024 Abandoned
Array ( [id] => 19798901 [patent_doc_number] => 20250064826 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-27 [patent_title] => NASAL COMPOSITIONS COMPRISING ALCAFTADINE [patent_app_type] => utility [patent_app_number] => 18/943165 [patent_app_country] => US [patent_app_date] => 2024-11-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8004 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18943165 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/943165
NASAL COMPOSITIONS COMPRISING ALCAFTADINE Nov 10, 2024 Pending
Array ( [id] => 19815033 [patent_doc_number] => 20250073240 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-06 [patent_title] => NEW TREATMENT [patent_app_type] => utility [patent_app_number] => 18/825447 [patent_app_country] => US [patent_app_date] => 2024-09-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16572 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18825447 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/825447
NEW TREATMENT Sep 4, 2024 Pending
Array ( [id] => 19815033 [patent_doc_number] => 20250073240 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-06 [patent_title] => NEW TREATMENT [patent_app_type] => utility [patent_app_number] => 18/825447 [patent_app_country] => US [patent_app_date] => 2024-09-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16572 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18825447 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/825447
NEW TREATMENT Sep 4, 2024 Pending
Array ( [id] => 19541641 [patent_doc_number] => 20240358677 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-31 [patent_title] => LASOFOXIFENE TREATMENT OF AROMATASE-RESISTANT ER+ CANCER [patent_app_type] => utility [patent_app_number] => 18/764277 [patent_app_country] => US [patent_app_date] => 2024-07-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11743 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18764277 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/764277
Lasofoxifene treatment of aromatase-resistant ER Jul 3, 2024 Issued
Array ( [id] => 19510434 [patent_doc_number] => 20240342120 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-17 [patent_title] => MULTIPLE MYELOMA TREATMENT [patent_app_type] => utility [patent_app_number] => 18/754044 [patent_app_country] => US [patent_app_date] => 2024-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 1898 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18754044 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/754044
MULTIPLE MYELOMA TREATMENT Jun 24, 2024 Pending
Array ( [id] => 19510442 [patent_doc_number] => 20240342128 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-17 [patent_title] => IMMUNE MEMORY INDUCTION BY PLATINUM BASED COMPOUNDS [patent_app_type] => utility [patent_app_number] => 18/751933 [patent_app_country] => US [patent_app_date] => 2024-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15773 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18751933 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/751933
IMMUNE MEMORY INDUCTION BY PLATINUM BASED COMPOUNDS Jun 23, 2024 Pending
Array ( [id] => 19845181 [patent_doc_number] => 20250090532 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-20 [patent_title] => SHP2 INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 18/655511 [patent_app_country] => US [patent_app_date] => 2024-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51839 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18655511 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/655511
SHP2 INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER May 5, 2024 Abandoned
Array ( [id] => 20356163 [patent_doc_number] => 12472142 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-18 [patent_title] => Liquid depot for non-invasive sustained delivery of agents to the eye [patent_app_type] => utility [patent_app_number] => 18/650914 [patent_app_country] => US [patent_app_date] => 2024-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 17 [patent_no_of_words] => 9813 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18650914 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/650914
Liquid depot for non-invasive sustained delivery of agents to the eye Apr 29, 2024 Issued
Array ( [id] => 19860639 [patent_doc_number] => 20250099425 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-27 [patent_title] => PHARMACEUTICAL COMPOSITIONS FOR TREATING CYSTIC FIBROSIS [patent_app_type] => utility [patent_app_number] => 18/643207 [patent_app_country] => US [patent_app_date] => 2024-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55379 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18643207 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/643207
PHARMACEUTICAL COMPOSITIONS FOR TREATING CYSTIC FIBROSIS Apr 22, 2024 Pending
Array ( [id] => 19860639 [patent_doc_number] => 20250099425 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-27 [patent_title] => PHARMACEUTICAL COMPOSITIONS FOR TREATING CYSTIC FIBROSIS [patent_app_type] => utility [patent_app_number] => 18/643207 [patent_app_country] => US [patent_app_date] => 2024-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55379 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18643207 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/643207
PHARMACEUTICAL COMPOSITIONS FOR TREATING CYSTIC FIBROSIS Apr 22, 2024 Pending
Array ( [id] => 19359259 [patent_doc_number] => 20240261293 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-08 [patent_title] => COMPOSITION CONTAINING LAMOTRIGINE, AND PREPARATION METHOD AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/638097 [patent_app_country] => US [patent_app_date] => 2024-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7931 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18638097 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/638097
COMPOSITION CONTAINING LAMOTRIGINE, AND PREPARATION METHOD AND USE THEREOF Apr 16, 2024 Pending
Array ( [id] => 19658451 [patent_doc_number] => 20240425516 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-26 [patent_title] => SALTS, CRYSTAL FORMS, AND PRODUCTION METHODS THEREOF [patent_app_type] => utility [patent_app_number] => 18/636653 [patent_app_country] => US [patent_app_date] => 2024-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35322 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18636653 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/636653
SALTS, CRYSTAL FORMS, AND PRODUCTION METHODS THEREOF Apr 15, 2024 Abandoned
Array ( [id] => 19387843 [patent_doc_number] => 20240277713 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-22 [patent_title] => Methods of Administering Belumosudil for Treatment of Chronic Graft Versus Host Disease in Patient Subpopulations [patent_app_type] => utility [patent_app_number] => 18/618767 [patent_app_country] => US [patent_app_date] => 2024-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21796 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18618767 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/618767
Methods of Administering Belumosudil for Treatment of Chronic Graft Versus Host Disease in Patient Subpopulations Mar 26, 2024 Pending
Array ( [id] => 19316771 [patent_doc_number] => 20240238311 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-18 [patent_title] => AQUEOUS PHARMACEUTICAL FORMULATION OF HYDROCORTISONE SODIUM PHOSPHATE AND MONOTHIOGLYCEROL [patent_app_type] => utility [patent_app_number] => 18/611251 [patent_app_country] => US [patent_app_date] => 2024-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47587 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18611251 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/611251
AQUEOUS PHARMACEUTICAL FORMULATION OF HYDROCORTISONE SODIUM PHOSPHATE AND MONOTHIOGLYCEROL Mar 19, 2024 Pending
Array ( [id] => 19332563 [patent_doc_number] => 20240246993 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-25 [patent_title] => CDK Inhibitors And Their Use As Pharmaceuticals [patent_app_type] => utility [patent_app_number] => 18/600852 [patent_app_country] => US [patent_app_date] => 2024-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31008 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 559 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18600852 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/600852
CDK Inhibitors And Their Use As Pharmaceuticals Mar 10, 2024 Abandoned
Menu